Physician profile
Ari S Eckman
NPI 1386859585
$2,726.35
in general payments reported to CMS, 2019-2025
25 companies · $963 in 2025
The $963 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $104 · 2022: $44.87 · 2023: $547 · 2024: $814 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968 · Honoraria: $300 · Education: $56.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.11 |
| Honoraria | $300.00 |
| Education | $56.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $573.20 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Chiesi USA, INC. | $327.21 | 2025 | Mycapssa |
| Novo Nordisk INC | $301.47 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amneal Pharmaceuticals LLC | $228.15 | 2023-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $191.87 | 2019-2025 | |
| Amgen INC. | $175.51 | 2024-2025 | Evenity, Prolia, Tepezza |
| Astrazeneca Pharmaceuticals Lp | $141.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.57 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Ascendis Pharma Endocrinology INC | $93.12 | 2023-2025 | Yorvipath |
| Abbott Laboratories | $79.16 | 2023-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Medtronic, INC. | $72.98 | 2023-2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $58.89 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Pfizer INC. | $57.54 | 2024-2025 | |
| Corcept Therapeutics | $45.27 | 2020-2025 | Korlym |
| Insulet Corporation | $39.68 | 2023 | Omnipod |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $39.56 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $32.70 | 2025 | |
| Dexcom, INC. | $29.39 | 2023-2024 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $27.95 | 2019-2022 | |
| Abbvie INC. | $27.85 | 2019-2025 | |
| Globus Medical, INC. | $19.66 | 2025 | Senza |
| Mckesson Patient Care Solutions INC. | $19.13 | 2019 | |
| Beta Bionics, INC. | $18.64 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amryt Pharma Holdings Ltd | $14.85 | 2023 | Mycapssa |
| Merck Sharp & Dohme LLC | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Eckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.